These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 10399998)

  • 1. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.
    Flaker GC; Warnica JW; Sacks FM; Moyé LA; Davis BR; Rouleau JL; Webel RR; Pfeffer MA; Braunwald E
    J Am Coll Cardiol; 1999 Jul; 34(1):106-12. PubMed ID: 10399998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial.
    Lewis SJ; Sacks FM; Mitchell JS; East C; Glasser S; Kell S; Letterer R; Limacher M; Moye LA; Rouleau JL; Pfeffer MA; Braunwald E
    J Am Coll Cardiol; 1998 Jul; 32(1):140-6. PubMed ID: 9669262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators.
    Goldberg RB; Mellies MJ; Sacks FM; Moyé LA; Howard BV; Howard WJ; Davis BR; Cole TG; Pfeffer MA; Braunwald E
    Circulation; 1998 Dec; 98(23):2513-9. PubMed ID: 9843456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial.
    Hunt D; Young P; Simes J; Hague W; Mann S; Owensby D; Lane G; Tonkin A
    Ann Intern Med; 2001 May; 134(10):931-40. PubMed ID: 11352694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty.
    Bertrand ME; McFadden EP; Fruchart JC; Van Belle E; Commeau P; Grollier G; Bassand JP; Machecourt J; Cassagnes J; Mossard JM; Vacheron A; Castaigne A; Danchin N; Lablanche JM
    J Am Coll Cardiol; 1997 Oct; 30(4):863-9. PubMed ID: 9316510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
    Sacks FM; Pfeffer MA; Moye LA; Rouleau JL; Rutherford JD; Cole TG; Brown L; Warnica JW; Arnold JM; Wun CC; Davis BR; Braunwald E
    N Engl J Med; 1996 Oct; 335(14):1001-9. PubMed ID: 8801446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial.
    Lewis SJ; Moye LA; Sacks FM; Johnstone DE; Timmis G; Mitchell J; Limacher M; Kell S; Glasser SP; Grant J; Davis BR; Pfeffer MA; Braunwald E
    Ann Intern Med; 1998 Nov; 129(9):681-9. PubMed ID: 9841599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.
    Ridker PM; Rifai N; Pfeffer MA; Sacks FM; Moye LA; Goldman S; Flaker GC; Braunwald E
    Circulation; 1998 Sep; 98(9):839-44. PubMed ID: 9738637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
    Kang S; Liu Y; Liu XB
    Clin Ther; 2013 Aug; 35(8):1125-36. PubMed ID: 23932462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
    Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in coronary events during treatment with pravastatin. PLAC I and PLAC II Investigators. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries.
    Furberg CD; Pitt B; Byington RP; Park JS; McGovern ME
    Am J Cardiol; 1995 Sep; 76(9):60C-63C. PubMed ID: 7572689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.
    Sacks FM; Tonkin AM; Shepherd J; Braunwald E; Cobbe S; Hawkins CM; Keech A; Packard C; Simes J; Byington R; Furberg CD
    Circulation; 2000 Oct; 102(16):1893-900. PubMed ID: 11034935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
    Plehn JF; Davis BR; Sacks FM; Rouleau JL; Pfeffer MA; Bernstein V; Cuddy TE; Moyé LA; Piller LB; Rutherford J; Simpson LM; Braunwald E
    Circulation; 1999 Jan; 99(2):216-23. PubMed ID: 9892586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study).
    Arntz HR; Agrawal R; Wunderlich W; Schnitzer L; Stern R; Fischer F; Schultheiss HP
    Am J Cardiol; 2000 Dec; 86(12):1293-8. PubMed ID: 11113401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency.
    Tonelli M; Moyé L; Sacks FM; Kiberd B; Curhan G;
    Ann Intern Med; 2003 Jan; 138(2):98-104. PubMed ID: 12529091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).
    Sacks FM; Pfeffer MA; Moye' L; Brown LE; Hamm P; Cole TG; Hawkins CM; Braunwald E
    Am J Cardiol; 1991 Dec; 68(15):1436-46. PubMed ID: 1746424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.
    Shepherd J
    Am J Cardiol; 1995 Sep; 76(9):113C-117C. PubMed ID: 7572679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
    Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.